ENDRA Life Sciences Inc. (NDRA)
| Market Cap | 45.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.90M |
| Shares Out | 23.89M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $1.74 |
| Previous Close | $1.05 |
| Change ($) | 0.69 |
| Change (%) | 65.71% |
| Day's Open | 1.29 |
| Day's Range | 1.19 - 1.75 |
| Day's Volume | 17,390,802 |
| 52-Week Range | 0.63 - 1.99 |
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:...
ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Franco...
ANN ARBOR, MI / ACCESSWIRE / December 23, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued Chinese Pat...
Supports Commercialization of TAEUS Ⓡ Product for Imaging NAFLD/NASH to December 2023 ANN ARBOR, MI / ACCESSWIRE / December 21, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pione...
ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously...
ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q3 2020 Results - Earnings Call Transcript
ENDRA Life Sciences Inc.'s (NDRA) CEO Francois Michelon on Q2 2020 Results - Earnings Call Transcript
TAEUS device fills the need for a non-invasive test for NASH.
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q1 2020 Results - Earnings Call Transcript
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q1 2020 Results - Earnings Call Transcript
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q4 2019 Results - Earnings Call Transcript
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q4 2019 Results - Earnings Call Transcript
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript
ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript
ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q2 2019 Results - Earnings Call Transcript
ENDRA released data at the end of 2019Q1 that didn't live up to the market's expectation, sending its share price down to new lows.
ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2019 Results - Earnings Call Transcript
About NDRA
ENDRA Life Sciences develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to gu... [Read more...]
| Industry Diagnostics & Research | IPO Date May 9, 2017 |
| CEO Francois Michelon | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol NDRA |
Analyst Forecasts
According to 3 analysts, the average rating for NDRA stock is "Strong Buy." The 12-month stock price forecast is 5.17, which is an increase of 197.13% from the latest price.